Price
125.03
+3.33%52W Range
Market Cap
₹669.52 Cr
Traded: ₹1.08 Cr (0.16%) 0.0x
Free Float: ₹194.03 Cr (0.55% of FF traded)
Volume · 60D trend
86.6 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +8.0% | +7.0% | +5.0% | -- | -- | Decelerating |
| Return | -- | +19.0% | -5.0% | +45.0% | -- | Stable |
| Profit | -7.0% | -17.0% | -44.0% | -- | -61.0% | Decelerating |
| Sales | +3.0% | +4.0% | -2.0% | -- | +8.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 94 | 105 | 109 | 89 | 72 | 109 | 96 | 92 | 82 | 118 | 96 | 86 | 67 | 105 | 101 | 99 |
| Expenses | 92 | 98 | 96 | 83 | 68 | 94 | 85 | 83 | 74 | 102 | 85 | 77 | 63 | 90 | 88 | 87 |
| Operating Profit | 2 | 7 | 13 | 6 | 4 | 15 | 12 | 10 | 8 | 16 | 12 | 9 | 5 | 15 | 13 | 12 |
| OPM % | 2.6% | 6.8% | 11.8% | 6.5% | 5.9% | 13.4% | 12.0% | 10.3% | 9.8% | 13.3% | 12.0% | 10.9% | 7.2% | 14.7% | 13.0% | 12.3% |
| Other Income | 1 | 6 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 1 |
| Interest | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 1 | 2 | 1 | 2 | 1 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 4 | 4 |
| Profit Before Tax | -6 | 5 | 6 | -0 | -2 | 8 | 6 | 3 | 1 | 11 | 7 | 5 | 0 | 10 | 10 | 8 |
| Tax % | -28.0% | 24.3% | 27.3% | 23.5% | -22.6% | 39.7% | 30.0% | 19.6% | 27.4% | 26.5% | 31.8% | 23.7% | -22.2% | 27.2% | 33.9% | 31.4% |
| Net Profit | -4 | 4 | 4 | -0 | -2 | 5 | 4 | 2 | 1 | 8 | 5 | 4 | 0 | 7 | 7 | 5 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | -0.8 | 0.7 | 0.9 | -0.1 | -0.4 | 1.0 | 0.8 | 0.5 | 0.2 | 1.7 | 1.0 | 0.8 | 0.1 | 1.5 | 1.4 | 1.1 |
| Sales Growth (YoY) | 31.2% | -3.2% | 12.8% | -3.7% | -12.3% | -7.8% | 0.0% | 7.3% | 21.3% | 11.8% | -4.6% | -13.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -10.5% | -3.1% | 22.5% | 23.6% | -34.0% | 12.9% | 4.5% | 12.6% | -30.6% | 22.4% | 12.2% | 27.3% | -36.0% | 4.4% | 1.6% | -- |
| OP Growth (YoY) | -42.4% | -50.8% | 10.8% | -39.6% | -47.1% | -6.7% | 0.2% | 2.1% | 66.8% | 1.3% | -11.9% | -23.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | -65.9% | -43.9% | 122.4% | 35.5% | -70.9% | 26.3% | 21.3% | 18.5% | -48.6% | 35.6% | 23.7% | 93.6% | -68.8% | 17.9% | 6.9% | -- |
| Profit Growth (YoY) | -115.0% | -23.0% | 10.0% | -118.0% | -308.0% | -40.0% | -16.0% | -43.0% | 291.0% | 12.0% | -28.0% | -24.0% | -96.0% | 3.0% | 62.2% | 67.0% |
| EPS Growth (YoY) | -97.4% | -30.0% | 9.8% | -118.4% | -311.1% | -39.8% | -16.3% | -42.4% | 260.0% | 11.4% | -27.4% | -24.1% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -207.1% | -22.2% | 1100.0% | 76.3% | -138.0% | 21.9% | 67.3% | 172.2% | -89.2% | 69.4% | 15.3% | 1600.0% | -96.6% | 10.4% | 20.5% | -- |
| OP Margin | 2.6% | 6.8% | 11.8% | 6.5% | 5.9% | 13.4% | 12.0% | 10.3% | 9.8% | 13.3% | 12.0% | 10.9% | 7.2% | 14.7% | 13.0% | 12.3% |
| Net Margin | -4.3% | 3.5% | 4.0% | -0.5% | -2.6% | 4.5% | 4.2% | 2.6% | 1.1% | 6.9% | 5.0% | 4.8% | 0.3% | 6.9% | 6.5% | 5.5% |
| Material Cost % | 41.9% | 44.8% | 44.7% | 44.7% | 41.8% | 44.4% | 42.8% | 45.7% | 44.3% | 47.7% | 45.9% | 46.5% | 46.1% | 47.0% | 50.9% | 52.4% |
| Employee Cost % | 20.4% | 16.5% | 14.3% | 18.4% | 20.4% | 15.0% | 15.0% | 16.8% | 17.7% | 12.5% | 13.7% | 14.9% | 18.7% | 12.7% | 11.7% | 12.0% |
| P/S | 1.69 | 1.64 | 1.38 | 0.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 164.51 | 101.29 | 68.12 | 51.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.25 | 2.06 | 2.07 | 1.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Transcript of Q1 FY27 Earning Conference call
Please find enclosed the Outcome of Postal Ballot .
Please find enclosed the Scrutinizer''s Report and Voting Results of Postal Ballot.
Please find enclosed the disclosure for the Link of Audio recording of Earnings Call Q1FY27.
Please find enclosed the copy of Newspaper Publication for the financial results for the quarter ended 30th June 2026.
Please find enclosed the Unaudited Financial Results for the Quarter ended 30th June 2026.
Please find enclosed the disclosure under Regulation 30 of SEBI LODR Regulations regarding Earnings Presentation for Q1 FY 27
Please find enclosed the Financial Results for the Quarter ended 30th June 2026.
Please find enclosed the disclosure regarding allotment of equity shares of the Company pursuant to exercise of stock options by the eligible employees under ZIM Laboratories Employee Stock ....
Please find enclosed the copy of newspaper publication regarding the Notice of Postal Ballot
Certificate under Reg 74(5) of SEBI (DP) Regulations,2018 for the quarter ended 30th June 2026 is enclosed herewith.
Please find enclosed the Postal Ballot Notice of the Company, for your reference.
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting
Please find enclosed the Voting Results under Regulation 44 of SEBI (LODR) Regulations 2015 along with the Scrutinizers Report of the 42nd Annual General Meeting of the Company held on 29th June 2026
Please find enclosed the Proceedings of the 42nd Annual General Meeting held on 29th June 2026 along with the Scrutinizers Report.
Please find enclosed the intimation regarding the Closure of trading window
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Anwar Daud
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting
Please find enclosed the schedule of investor meet to be held on 17th June 2026 at 4:00 pm
Please find enclosed Newspaper Publication regarding the 42nd Annual General Meeting.
Please find enclosed the Annual Report for the F.Y. 2025-26.
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Pursuant to Regulation 36(1)(b) of SEBI(LODR) Regulations 2015 please find enclosed the letter sent to members providing weblink of Annual Report for F.Y. 2025-26
The Notice of 42nd Annual General Meeting along with the Annual Report for the F.Y 2025-26 is enclosed.
Corrigendum to the Newspaper Publication dated 26.05.2026
Copy of Newspaper Advertisement intimating 42nd Annual General Meeting scheduled to be held on Friday 26th June,2026 through VC/OAVM.
Transcript of Q4 & FY26 Earnings Conference Call
Please find enclosed the copies of newspaper publication regarding the financial results for the quarter and year ended 31.03.2026
Enclosed the disclosure with the link for the audio recording of the Q4 & FY26 Earnings Conference Call
Outcome of the Board meeting held on 19.05.2026
Appointment of M/s. Dhananjay V. Joshi & Associates, Cost Accountants as the Cost Auditor for the F.Y. 2026-27
Pursuant to Regulation 33, please find attached the Financial Results (Standalone and Consolidated) of the Company for the year ended 31.03.2026
Please find attached a press release dated 19th May 2026 titled "ZIM Laboratories Limited announces grant of Marketing Authorization (MA) for Dabigatran Etexilate (75 mg, 110 mg &150 mg) ....
Disclosure under Regulation 30 of SEBI LODR regarding earnings presentation for Q4 & FY26.
Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that Q4&FY26 Earnings ....
Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve the audited standalone and ....
This is to inform that the manufacturimg facility of the Company underwent an inspection conducted by German and Portuguese Authority. The inspection commenced from 04th May, 2026 and concluded ....
The Nomination and Remuneration Committee of the Board on 08.05.2026 has approved the grant of 1,29,200 options to the eligible employee of the Company under the ZIM Laboratories Employee ....
Pursuant to Regulation 30 of SEBI (LODR) Regulations, please find enclosed the disclosure w.r.t allotment of 48,726 equity shares pursuant to exercise of options under ZIM Laboratories ....
In continuation of the disclosures dt. 13.05.2024 and 02.07.2024, we wish to inform you that out of the approved investment amount of upto Rs. 2 crores, the Company has invested Rs. 89,45,100 ....
Certificate under Reg.74 (5) of SEBI (DP) Regulations, 2018 is enclosed herewith for the quarter ended 31st March 2026.
The disclosure under Regulation 30 of SEBI (LODR) Regulations 2015, regarding the appointment of Grant Thornton Bharat LLP as the Internal Auditors of the Company is enclosed herewith.
Please find enclosed the intimation regarding Closure of trading window.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mathew Cyriac & PACs
Intimation of schedule of Investor meet to be held on Friday, 20th March, 2026
Disclosure regarding allotment of equity shares as per enclosed details
We hereby inform that the DMCC Authority has approved the closure (dissolution) of ZIM Laboratories Middle East DMCC, step down subsidiary of the Company.
Pursaunt to Regulation 30 of SEBI (Listing Obligations and Disclsoure Requirements) Regulations, 2015, please find attached the disclosure with respect to Credit Rating, for your reference.
Annual Reports
12Credit Ratings
6Concalls
16Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Feb 2019
28 Feb 2019Dec 2018
31 Dec 2018